clinical trial · NCT07356037
Nanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma
Changchun GeneScience Pharmaceutical Co., Ltd.·phase3·not yet recruiting·n = 68
CachexiaHepatocellular CarcinomaNanocrystalline Megestrol AcetateStandard Antitumor Therapy
brief summary
This study is a prospective, randomized, parallel-controlled clinical trial. The primary objective is to evaluate the superiority and safety of nanocrystalline megestrol acetate in combination with standard therapy compared with standard therapy alone in improving appetite and body mass index (BMI) during treatment in patients with early-stage or locally advanced hepatocellular carcinoma at the cachexia stage.
started
Jan 10, 2026
primary completion
Jun 30, 2027
completion
Dec 31, 2027
last updated
Jan 21, 2026
official title
A Prospective Clinical Study of Nanocrystalline Megestrol Acetate in Combination With Standard Therapy Versus Standard Therapy Alone for Cachectic Stage Locally Advanced Hepatocellular Carcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol